Biotie Completes Enrollment in Phase 2b Trial of Tozadenant in Parkinson's Disease

Biotie Therapies Corp.         Stock Exchange Release         5 July 2012  at
09:00 a.m.



Biotie Completes Enrollment in Phase 2b Trial of Tozadenant in Parkinson's
Disease

Biotie today announced that enrollment is complete in its Phase 2b trial
evaluating the safety and efficacy of tozadenant in Parkinson's disease ("PD").
Biotie now expects the top-line data from this study to be available at around
the end of 2012, previous guidance was H1 2013.

The 12 week, double-blind, placebo-controlled, dose-finding study, being
conducted in the US, Canada, Chile, Argentina, Ukraine and Romania, enrolled
420 PD patients experiencing levodopa related end of dose wearing off. In these
patients, treatment with levodopa is insufficient to control PD symptoms until
their next dose, resulting in an 'off' period when symptoms reappear. The
primary goal of the Phase 2b study is to determine the efficacy of tozadenant in
reducing the mean number of hours per day spent in the 'off' state. The trial
will also assess the safety of tozadenant and its impact on various measures of
motor symptom severity, dyskinesia and non-motor symptoms.

"Thanks to the dedication of our investigators and staff, recruitment in this
large study has been completed earlier than anticipated." said Timo Veromaa,
President and CEO of Biotie. "We look forward to finalizing the study and
evaluating the potential of tozadenant as a treatment for Parkinson's disease."

Biotie has granted UCB Pharma S.A. a license for exclusive, worldwide rights to
tozadenant. Pending evaluation of the results of the ongoing study UCB Pharma
will be responsible for conducting the Phase 3 program and commercializing
tozadenant.

In Turku, 5 July 2012

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Dr. Stephen Bandak, Chief Medical Officer
tel. +1 650 296 0946 (Pacific Daylight Time)
email: stephen.bandak@biotie.com

Virve Nurmi, IR Manager
tel. +358 2 274 8900, email: virve.nurmi@biotie.com
www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

About tozadenant (SYN115)

Tozadenant is an oral, potent and selective adenosine A2a receptor antagonist,
which enters the brain and modulates regions associated with motor and non-motor
function. Biotie obtained development and commercialization rights to tozadenant
from Roche in 2007 for selected diseases of the central nervous system.

About Parkinson's disease

Parkinson's disease is the second most common neurodegenerative disorder, after
Alzheimer's disease. It affects about one percent of people ages 65-69, rising
to up to three percent of people who are 80 years and older. The symptoms of
Parkinson's disease result from decreased dopamine production in regions of the
brain controlling movement.

About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post traumatic stress disorder), and inflammatory and fibrotic
liver disease.The company has a strong and balanced development portfolio with
several innovative small molecule and biological drug candidates at different
stages of clinical development. Biotie's products address diseases with high
unmet medical need and significant market potential.

Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant
for Parkinson's disease. The Marketing Authorization Application for Biotie's
most advanced product, SelincroTM (nalmefene) for alcohol dependence was filed
in the EU by our partner H. Lundbeck A/S and was accepted for review by the
European Medicines Agency in December 2011. Biotie shares are listed on NASDAQ
OMX Helsinki Ltd.




[HUG#1624103]